GeneDx Holdings Corp.
WGSHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGeneDx Holdings Corp., a genomics company, provides genetic testing services. At a $1.88B market cap, GeneDx Holdings Corp. ranks as a small-cap company within healthcare. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Market Cap
$1.88B
Beta
1.91
P/E (TTM)
—
P/E (Fwd)
57.51
EPS (TTM)
$-2.74
EPS (Fwd)
$1.10
ROE
-30.4%
ROA
-4.4%
Cash
$170.7M
Total Debt
$168.2M
Free CF
$3.6M
52W Change
-18.5%
Annual Financials
Cash vs Debt
With $170.7M in cash and $168.2M in debt, WGS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $3.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -30.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $234.7M (2022) to $427.5M (2025), reflecting a 82% increase over the period.
GeneDx Holdings Corp.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GeneDx Holdings Corp.'s trajectory.